Explore Rinvoq as a Promising Option for Atopic Dermatitis Relief

Are you or a loved one aged 18-64 struggling with moderate-to-severe Atopic Dermatitis that hasn’t responded adequately to Dupixent? This SWITCH-UP clinical trial offers a unique opportunity to explore a new treatment with Rinvoq. Participants will benefit from cutting-edge care, contribute to essential research, and receive compensation for their involvement. Be a part of this transformative study aimed at advancing skin health.

New York location for dermatology study by Equity Medical
Study Location
New York
Office Address

200 Amsterdam Ave. New York, NY 10023

Office Phone
646-413-6020

Overview

Recruiting start date
  • 8/1/24
Duration
  • 32 Weeks
Population

Individuals aged 18-64 with moderate-to-severe Atopic Dermatitis (AD) that has shown inadequate response to Dupixent.

Study Drug

Rinvoq 15 -> 30mg (50%) or Dupixent (50%) monotherapy.

Study Design

Open-label, efficacy assessor-blinded study evaluating Rinvoq initiated at 15 mg compared to Dupixent monotherapy in patients with inadequate response to dupilumab after at least 6 months of current use (last dose within 2 weeks prior to study Baseline). Patients deemed to not have an adequate response switch to Rinvoq at week 8.

Special Criteria
  • Chronic AD with inadequate response to Dupilumab treatment after at least 6 months.

Compensation
  • Participants will receive $75 per visit.
Studies
Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!